Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Lung Transplant Foundation, FDA Confer About BOS

The Lung Transplant Foundation is hosting a meeting with the U.S. Food and Drug Administration (FDA) with the intent of educating the agency and public about the challenges of living with bronchiolitis obliterans syndrome (BOS), a severe complication of lung transplants. “This is the first time that regulators and policymakers…

High Variability Found in People With F508del/5T;TG12 Genotype

There is wide clinical variety in the presentation of individuals who carry one F508del mutation and one 5T;TG12 mutation in the CFTR gene, an Italian study highlights. Its researchers stressed the need to monitor individuals with this genotype, since there are not currently accurate ways to predict who is at highest risk…

New Spectroscopy Method May Help Identify CF Bacteria Faster

Scientists at the University of Southampton have created a new method that could be useful for rapidly identifying infectious bacteria in samples from people with cystic fibrosis (CF). Unlike currently used methods, this method does not require a time-consuming culture step where bacteria are grown in a laboratory. The…

Targeting Pathway With Ectoine May Help in Stabilizing CFTR Protein

A natural compound called ectoine may help to improve the stability of the CFTR protein by modulating the activity of a molecular signaling pathway called AREG-EGFR-ERK, a study reported. Ectoine is a stress-protection molecule with water-retaining and potentially anti-inflammatory properties. The researchers suggested that ectoine, given in combination with CFTR…

Canada Approves Trikafta for Children 6 and Older

Health Canada has expanded the approval of Vertex Pharmaceuticals‘ triple-combination modulator treatment Trikafta to cover children with cystic fibrosis (CF) as young as 6 who have at least one copy of the F508del mutation. Trikafta had been approved only for patients ages 12 and older in Canada. According to…